FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

被引：0
|
作者：
Lacombe, C. [1 ]
Perrier, M. [2 ]
Hentic, O. [1 ]
Brixi, H. [2 ]
Rebours, V [1 ]
Cadiot, G. [2 ]
Ruszniewski, P. [1 ]
de Mestier, L. [1 ]
机构：
[1] Univ Paris, Beaujon Hosp, APHP Nord, Dept Gastroenterol Pancreatol, Clichy, France
[2] Univ Reims, Robert Debre Hosp, Dept Hepatogastroenterol & Digest Oncol, Reims, France
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
neuroendocrine tumor; antiangiogenic therapy; vegf; well-differentiated;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I17
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [21] The treatment of metastatic neuroendocrine tumors:: Activity of a combination chemotherapy
    Procopio, G
    Catena, L
    Di Bartolomeo, M
    Artale, S
    Ferrari, L
    Martinetti, A
    Ferrario, E
    Stani, SC
    Alù, M
    Buzzoni, R
    Celio, L
    Bajetta, E
    ANNALS OF ONCOLOGY, 2000, 11 : 61 - 61
  • [22] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
    Shi, Sha
    Lu, Kemei
    Gao, Hui
    Sun, Huidong
    Li, Senlin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
  • [23] Bevacizumab and Subtype-Adapted Chemotherapy Backbone in Neuroendocrine Tumors Reply
    Chan, Jennifer A.
    Kulke, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 977 - 978
  • [24] Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors
    Collot, Thomas
    Fumet, Jean-David
    Klopfenstein, Quentin
    Vincent, Julie
    Bengrine, Leila
    Ghiringhelli, Francois
    ANTICANCER RESEARCH, 2018, 38 (10) : 5963 - 5968
  • [25] Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
    Saltz, Leonard
    Badarinath, Suprith
    Dakhil, Shaker
    Bienvenu, Bryan
    Harker, W. Graydon
    Birchfield, George
    Tokaz, Laurence K.
    Barrera, David
    Conkling, Paul R.
    O'Rourke, Mark A.
    Richards, Donald A.
    Reidy, Diane
    Solit, David
    Vakiani, Efsevia
    Capanu, Marinella
    Scales, Amy
    Zhan, Feng
    Boehm, Kristi A.
    Asmar, Lina
    Cohn, Allen
    CLINICAL COLORECTAL CANCER, 2012, 11 (02) : 101 - 111
  • [26] Bevacizumab Chemotherapy for the Treatment of Newly Diagnosed and Progressive Primary Brain Tumors
    Newton, Herbert B.
    Lima, Judy
    Cunningham, Heather
    Brooks, Daniel
    NEUROLOGY, 2011, 76 (09) : A98 - A98
  • [27] Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors.
    Hoe, Hui Jing
    Wyld, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16212 - E16212
  • [28] Experience with Bevacizumab in Neuroendocrine Tumors
    Apostolidis, L.
    Jaeger, D.
    Winkler, E. C.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 127 - 127
  • [29] Metastatic pancreatic neuroendocrine tumors and chemotherapy: evidences and perspectives - Reply
    Salazar, Ramon
    MEDICINA CLINICA, 2007, 128 (09): : 357 - 358
  • [30] A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors
    Kunz, P. L.
    Kuo, T.
    Zahn, J. M.
    Kaiser, H. L.
    Norton, J. A.
    Visser, B. C.
    Longacre, T. A.
    Ford, J. M.
    Balise, R. R.
    Fisher, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345